Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Each to their own, I've always been here to see the end of chemo, COVID sideline is just that. Long term investors and those who have taken the time to research the company understand the potential of their mouse generating antibody platform and scope to treat multiple autoimmune conditions. 97% of drugs fail testing, none of them had the benefit of screening their products using humanised mice and thoroughly validating candidates prior to human phases. Game changer.
"The hard truth of drug development by #startup #Biotechnology companies is that it takes time and significant resources. There are just a handful known to me companies that were able to drastically reduce both" *Vlad ;-)
https://t.co/UL6KFxuDDi
If all these bags were nailed for this year I suspect you would be getting holding rns from time to time as the big boys jump in. This may not be aim but it is nonetheless a penny stock. Perhaps it will be one of the very few to make it eventually but let's face it without covid bringing these plays to the fore this would be around 3p. Just a little reality. Most penny stocks do not make it and often when they do shareholders get mugged. Been in far too many sure fire baggers that have cost me dear. 20%+ is a good return. Hope you guys get your dream and I will be genuinely happy for you. But long term has not worked for me before. If a sudden rns pops and this bags I would however leave some to ride on the off chance.
Completely agree , although my knowledge is limited I can easily see a positive Covid update reach 70/80p.
JHFH I absolutely love your posts & positivity backed by facts. Please keep them coming, on behalf of this board ... a massive thank you.
As for those selling, I cannot understand why you would risk losing out on BIG money for the sake of a couple of hundred quid.
Wonder if superwoman got her shares in at 7p or still having too much fun on other stocks - either way, I don’t miss her comments !
Good luck all, hopefully 10p by close today.
People have their timescales and facts wrong. SNG have done phase 2 trials which incorporated some elements of Phase 3. 15 years of work have gone into their treatment. They are likely to be fast tracked for approvals as the treatment has strong signs of success treating covid as well as COPD.
Hemo are pre-clinical/phase 1 so no where near SNG's development, these companies are not similar and so should't be compared in my view.
At some point with the right news hopefully covid connected...the sp will go up in leaps ie 20p to 40p to 100p. Anymore will depend on the bashers and rampers tug o' war?
I know i will win.....
•¿•
Agreed bdcarr, now hemo have the resources they can build phase 1 value themselves and open a bidding war for phase ii. Amd who knows, with sufficient capital from CDX and maybe COVID they may have ability to progress to phase ii on their own :-)
To be in perspective here. if HEMO has a billion buyout, that equates to £2.30 per share and currently SNG with a billion buyout, its £6+ per share.
T-Cell buyouts are usually multiple Billions as a previous post said and therefore this share is totally undervalued in my view. As JHFH says, its a possible Golden Egg waiting to hatch.
Covid & Lilly announcements could see this jump to 50-70p, just like SNG.
Probably you all heard about Synairgen, who worked with University Hospital Southampton on clinical trial Ph1. Yes it is Covid so urgency is different, but timelines were Ph1 start announced March 2020. Positive first results Jul 2020. SP went from 6p to 210p now. Analogy is the same with Hemo and University of Pennsylvania. And this is only one of their pipelines, we did not even expect news from it.
Working with a Principal Investigator directly on a trial runs at different interest and is much quicker to achieve results.
Positive PoC will drive to Phase1 the SP will rocket on this news itself.
Potential here is bigger than selling at 9p :)
DYOR